✦ LIBER ✦

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials

✍ Scribed by Pujol, Jean-Louis; Barlesi, Fabrice; Daurès, Jean-Pierre

Book ID: 119319327
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 163 KB
Volume: 51
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2005.11.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PD-079 Should chemotherapy combinations

PD-079 Should chemotherapy combinations for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of phase III randomised trials

✍ Pujol, J.; Barlesi, F.; Daures, J. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Platinum-based combination chemotherapy

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B

✍ Green, Mark R. ;Kramar, Andrew ;Schilsky, Richard ;Stoopler, Marc ;Zimmer, Bonni 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received

A meta-analysis of randomized controlled

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

✍ Jiang, Jingwei; Liang, Xiaohua; Zhou, Xinli; Huang, Ruofan; Chu, Zhaohui 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 967 KB

Weekly docetaxel as second line chemothe

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials

✍ Emilio Bria; Federica Cuppone; Mariangela Ciccarese; Cecilia Nisticò; Francesco 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Eligibility of patients with advanced no

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

✍ Janette Vardy; Ryan Dadasovich; Philip Beale; Michael Boyer; Stephen J Clarke 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 187 KB

Gefitinib vs. chemotherapy as first-line

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

✍ Ku, Geoffrey Y.; Haaland, Benjamin A.; de Lima Lopes, Gilberto 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 281 KB